ArticleBMC neurology2025
Novel prognostic score based on the monocyte-to-lymphocyte ratio and CAVE score for epilepsy after primary intracerebral hemorrhage.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selected Molecular Targets for Counteracting Epileptogenesis: What Do We Know About Its Effective Inhibition?Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeuroinflammation-mediated epilepsy has become a focus of attention in recent years. Post-stroke epilepsy (PSE) is common, with most studies focusing on ischemic stroke rather than intracerebral hemorrhage (ICH) patients. Therefore, we aimed to determine the association between monocyte-to-lymphocyte ratio (MLR) levels and epilepsy after ICH. Additionally, we sought to develop a clinical score integrating MLR with the CAVE score to improve the risk stratification of PSE.
methodsWe retrospectively included consecutive ICH patients from January 2010 to July 2020. MLR was acquired from a routine blood test at admission. Multiple logistics and linear regression analyses were performed to identify risk factors for the PSE when MLR levels were divided into tertiles. Receiver operating characteristic (ROC) curves were used to assess the predictive accuracy of epilepsy models based on the CAVE score and the MNCAVE score.
resultsAmong the 834 patients with ICH, 47 (5.6%) patients had PSE. In multivariable logistics and linear regression analysis, elevated MLR levels were independently associated with the PSE after adjusting for several confounders (OR 2.545, 95% CI 1.036-6.255, P = 0.042). Six risk factors were selected to derive the MNCAVE score (higher MLR, severe stroke, cortical location, young age, large hematoma volume, and early seizures), which showed better prognostic performance than the conventional CAVE score (0.875 vs. 0.848, P = 0.041).
conclusionsElevated MLR levels were associated with PSE after ICH. We developed the MNCAVE score for predicting PSE, which could improve the management of patients after ICH. Inflammatory markers may provide personalized guidance for patients with varying degrees of neurological impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.